Lymphoma, T-Cell, Peripheral
"Lymphoma, T-Cell, Peripheral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.
| Descriptor ID |
D016411
|
| MeSH Number(s) |
C04.557.386.480.750.825 C15.604.515.569.480.750.825 C20.683.515.761.480.750.825
|
| Concept/Terms |
Lymphoma, T-Cell, Peripheral- Lymphoma, T-Cell, Peripheral
- T-Cell Lymphoma, Peripheral
- T Cell Lymphoma, Peripheral
- Lymphoma, T Cell, Peripheral
- Peripheral T-Cell Lymphoma
- Lymphoma, Peripheral T-Cell
- Lymphomas, Peripheral T-Cell
- Peripheral T Cell Lymphoma
- Peripheral T-Cell Lymphomas
- T-Cell Lymphomas, Peripheral
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, T-Cell, Peripheral".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, T-Cell [C04.557.386.480.750]
- Lymphoma, T-Cell, Peripheral [C04.557.386.480.750.825]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, T-Cell [C15.604.515.569.480.750]
- Lymphoma, T-Cell, Peripheral [C15.604.515.569.480.750.825]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, T-Cell [C20.683.515.761.480.750]
- Lymphoma, T-Cell, Peripheral [C20.683.515.761.480.750.825]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, T-Cell, Peripheral".
This graph shows the total number of publications written about "Lymphoma, T-Cell, Peripheral" by people in this website by year, and whether "Lymphoma, T-Cell, Peripheral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 0 | 3 |
| 2003 | 1 | 1 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 4 | 0 | 4 |
| 2013 | 7 | 0 | 7 |
| 2014 | 5 | 0 | 5 |
| 2015 | 4 | 0 | 4 |
| 2016 | 7 | 1 | 8 |
| 2017 | 5 | 0 | 5 |
| 2018 | 5 | 0 | 5 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 5 | 0 | 5 |
| 2022 | 8 | 0 | 8 |
| 2023 | 5 | 0 | 5 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, T-Cell, Peripheral" by people in Profiles.
-
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2024 Sep; 11(9):e671-e681.
-
Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study. Haematologica. 2024 01 01; 109(1):209-219.
-
Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma. Leuk Lymphoma. 2023 12; 64(14):2258-2268.
-
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma. Blood. 2023 08 17; 142(7):621-628.
-
Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy. Oncologist. 2023 06 02; 28(6):520-530.
-
The prognostic role of red cell distribution width on all-cause and cause-specific outcomes in peripheral T-cell lymphoma: a retrospective cohort study. Leuk Lymphoma. 2023 Jul-Aug; 64(7):1225-1233.
-
Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Arch Pathol Lab Med. 2023 01 01; 147(1):79-86.
-
Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source. Transplant Cell Ther. 2023 04; 29(4):267.e1-267.e5.
-
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. Oncologist. 2022 10 01; 27(10):864-873.
-
Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS. Haematologica. 2022 08 01; 107(8):1864-1879.